Neuraxis, INC 8-K filings

Neuraxis, Inc. announced a stock dividend for its Series B Preferred Stock, payable in common stock on July 29, 2026.

Neuraxis stockholders approved the election of six directors and ratified amendments to the company's incentive and employee stock purchase plans.

Neuraxis, Inc. has filed to increase its at-the-market equity offering capacity to an aggregate of $11.5 million.

Neuraxis, Inc. announced preliminary unaudited financial results for the first quarter of 2026, highlighting revenue growth to $1.6 million.

Neuraxis, Inc. announced FDA 510(k) clearance for its PENFS technology for functional abdominal pain and functional dyspepsia, and increased its At The Market offering capacity to $6.27 million.

Neuraxis, Inc. disclosed preliminary unaudited financial results for the third quarter and nine months ended September 30, 2025, showing increased year-to-date sales but a quarterly operating loss.

Neuraxis, Inc. has entered into an At The Market Offering Agreement to sell up to $3.3 million of common stock, providing flexible access to capital.

Neuraxis, Inc. has terminated its license and collaboration agreement with Masimo Corporation for the NSS-2 Bridge device, regaining full rights to the product, and simultaneously adopted a new Employee Stock Purchase Plan to foster employee ownership.

Neuraxis, Inc. announced that its stockholders approved all proposals at the Annual Meeting held on May 29, 2025, including the election of six directors, ratification of its independent auditor, and the issuance of common stock upon conversion of Series B Preferred Stock.

Neuraxis, Inc. has filed an 8-K report to announce the posting of an investor presentation on its website, providing an overview of the company's strategy, performance, and future objectives.

Neuraxis, Inc. has entered into definitive agreements for a $5.0 million registered direct offering of common stock.

Neuraxis, Inc. settles multiple lawsuits for $750,000 payable in monthly installments, and issues common stock from warrant exercises and preferred stock conversions.

Neuraxis Inc. reported a 50% year-over-year revenue increase for the fourth quarter of 2024, reaching approximately $800 thousand, and a full-year revenue of $2.7 million, up 11% from the previous year.

Neuraxis, Inc. has appointed Dr. Gil Aharon to its board of directors, effective January 1, 2025, following a $5 million investment from related investors.

Neuraxis Inc. has amended the terms of its Series B Preferred Stock, increasing the authorized shares, extending dividend rights, and modifying voting rights.

Neuraxis, Inc. has entered into agreements to issue $5 million worth of Series B Convertible Preferred Stock to related investors.

NeurAxis, a medical technology company, announced a 40% increase in revenue for the third quarter of 2024, driven by strong demand for its IB-Stim product.

Neuraxis, Inc. has amended its securities purchase agreement with Flagstaff International, reducing the total investment amount while also entering into new agreements with other investors for additional capital.

Neuraxis Inc. has converted approximately $4.9 million in promissory notes into 2,073,524 shares of Series B Preferred Stock following stockholder approval and the filing of necessary certificates.

Neuraxis, Inc. held its annual meeting where stockholders voted on and approved several key proposals, including the election of directors, ratification of the accounting firm, and amendments to the incentive plan and corporate charter.

NeurAxis, a medical technology company, announced its second quarter 2024 financial results, highlighting significant growth in insurance coverage despite a slight revenue decrease.

NeurAxis, Inc. granted unrestricted stock awards to its three non-employee directors as compensation for past services, marking the first issuance under its 2022 Omnibus Securities and Incentive Plan since its IPO.

Neuraxis, Inc. has entered into a securities purchase agreement for $3 million in convertible notes and amended the terms of its Series B Preferred Stock.

Neuraxis Inc. reports the immediate termination of its Chief Operating Officer, Dan Clarence, effective April 10, 2024, with severance and benefits continuation.

NeurAxis, Inc. announced its full year 2023 financial results, which included a restatement of prior financials due to a material accounting error, and highlighted significant growth in insurance coverage and clinical research progress.

Neuraxis, Inc. has amended its agreement with Flagstaff International, LLC, increasing the investment to $5 million through a convertible promissory note, replacing the previously planned Series B Preferred Stock issuance.

Neuraxis, Inc. has appointed Kristin Ferge as an independent director and chair of the Audit Committee, effective March 7, 2024.

Neuraxis, Inc. has amended its securities purchase agreement with Flagstaff International, LLC, securing a $3 million investment through a convertible promissory note.

NeurAxis, Inc. has appointed Timothy Henrichs as its new Chief Financial Officer, effective February 5, 2024, following his resignation from the Board of Directors.